Cancer Therapy
Kosan presents encouraging antitumor and safety data on novel epothilone KOS-1584 at EORTC
Published in Cancer Weekly, December 12th, 2006
KOS-1584 is being evaluated in two phase I trials using different dosing regimens with the goal of defining the recommended phase II dose and to assess safety, pharmacokinetics, pharmacodynamics, and early evidence of antitumor activity. Data on KOS-1584 were presented in posters at the 18th American Association for Cancer Research (AACR)-U.S. National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Symposium on "Molecular Targets and Cancer Therapeutics," in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-12-12)
More Articles from Cancer Weekly
- Cancer Therapy
Research identifies a human enzyme that could be programmed to kill cancer cells - Drug Development
Clinical data from Adherex's proof-of-mechanism and Phase I eniluracil trials presented - Ankylosing Spondylitis
Data shows Enbrel provides sustained clinical improvements for people with ankylosing spondylitis - Antifungal Agents
Noxafil (posaconazole) Oral Suspension approved in European Union for invasive fungal infections - Breast Cancer
BSD Medical reports greater success in treating breast cancer patients - Business & Finance
Chemokine Therapeutics announces third quarter financial and operating results - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
